Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology.
GALWAY, Ireland and CHICAGO, June 20, 2025 /PRNewswire/ — Medtronic, a global leader in healthcare technology, will present data at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, highlighting improved glycemic outcomes for individuals with insulin-intensive type 2 diabetes on the MiniMed™ 780G* system under investigational use. Participants in a clinical trial achieved an average 8.6% increase in Time in Range (TIR), reaching 84.9%, well above the ADA goal of 70%, and a HbA1C reduction from 7.7% to 6.9%, meeting ADA targets for diabetes management.
Figure 1: The bracketed values are the TIR of 70-180 mg/dL during the run-in phase, the manual mode period and the auto mode period. During manual mode, the suspend before low (SBL) feature was activated. During run-in, the system was also used in manual mode with SBL activated.
Separately, results from the Medtronic LENNY trial were publishedi in The Lancet Diabetes & Endocrinology. This multi-center, randomized controlled, crossover trial evaluated the MiniMed™ 780G system in young children (ages 2-6 years) with type 1 diabetes in a home setting. Results showed those using the MiniMed™ 780G system with SmartGuard™ achieved a 0.6% lower HbA1C and 9.9% higher Time in Range when compared to a baseline therapy of manual mode or hybrid closed loop without autocorrections. Parents and caregivers also reported improved sleep quality and lower fear of hypoglycemia when the system was used in auto mode (with SmartGuard™) compared to manual mode.
Benefits of automated insulin delivery (AID) systems for type 2 diabetesWhile the standard of care for type 2 diabetes often includes lifestyle modifications and oral medications, many individuals require intensive insulin therapy to achieve optimal glucose management.
The ADA’s 2025 Standards of Careii now endorse the use of AID systems for adults with insulin-intensive type 2 diabetes, recognizing their potential to significantly improve clinical outcomes — an important validation of the growing role of diabetes technology in transforming chronic disease management.
A 31-site single arm trial evaluated the MiniMed™ 780G system paired with the Simplera Sync™ sensor in a cohort of 236 individuals with type 2 diabetes. Results were promising across all clinical outcome metrics including Time in Range (TIR), Time in Tight Range (TITR), Time Above Range (TAR) compared to the run-in period where hybrid closed loop (auto basal only) or open-loop delivery was used. Time below range (TBR) remained stable.
“As the industry moves toward broader indications of automated insulin delivery systems, we see tremendous potential to improve outcomes and quality of life for millions of people managing type 2 diabetes with insulin,” said Dr. Robert Vigersky, Chief Medical Officer, Medtronic Diabetes. “Our teams are committed to advancing smart, connected technologies that reduce the daily burden of care and bring precision to insulin therapy like never before.”
|
Baselinea |
Studyb |
Change (Study – |
P |
|
|
Participants, N |
236 |
232 |
— |
— |
|
Time in AHCL, % |
— |
92.4 ± 15.7 |
— |
— |
|
A1C, % |
7.7 ± 0.9 |
6.9 ± 0.7c |
-0.8 ± 0.9c |
|